Find Your MAC! Add TransLabs as a preferred
source on Google
NGS Panel Billing

Billing Next-Generation Sequencing (NGS) Panels: PLA Codes, Prior Authorization, and Denial Traps

Billing NGS panels correctly starts with choosing the right code, something laboratory billing specialists like TransLabs focus on daily: a PLA code when the panel has one, a GSP code for defined multi-gene panels, or Tier 1/Tier 2 codes only when they genuinely fit, with 81479 as a last resort. Prior authorization thresholds vary by payer and often hinge on gene count, while missing Z-Code identifiers, mismatched diagnosis codes, and incomplete documentation drive most preventable denials. Because these rules shift quarterly, partnering with specialized NGS billing experts helps laboratories keep coding, MolDX registration, and prior authorization workflows current and protect reimbursement.

Introduction

If you have ever tried to get a next-generation sequencing panel paid for correctly on the first pass, you already know the punchline of this article. It almost never happens by accident. NGS billing sits at the intersection of some of the most complicated corners of the CPT and HCPCS code sets, a prior authorization landscape that changes payer by payer and sometimes month by month, and a documentation standard that is stricter than almost anything else in laboratory medicine.

That combination is exactly why so many laboratories, oncology practices, and genetic testing companies lose real revenue on tests they performed correctly. The science works. The billing doesn’t.

This guide walks through the three places where NGS panel billing most often breaks down: choosing between a Proprietary Laboratory Analyses (PLA) code and a Tier 2 molecular pathology code, navigating prior authorization thresholds that vary by payer and by panel size, and avoiding the denial traps that quietly drain reimbursement even when the test itself was medically appropriate. Along the way, we’ll cover the current coding landscape, what CMS and major commercial payers actually require in 2026, and how a laboratory can build a claims process that holds up under scrutiny, whether in-house or with specialized NGS billing experts.

NGS billing at a glance

  • Use the most specific code that accurately describes the test performed. A PLA or GSP code beats a stack of Tier 2 codes whenever one applies.
  • • Confirm whether a PLA, GSP, Tier 1/Tier 2, or unlisted 81479 pathway is the right fit before the claim goes out, not after a denial comes back.
  • • Check payer-specific prior authorization requirements, including gene count thresholds, before the specimen is even collected.
  • • Verify whether the payer or MAC requires a Z-Code or registry identifier (MolDX/DEX, Concert Genetics, or similar) and include it on the claim.
  • • Match the diagnosis code and supporting documentation to the specific medical necessity criteria the payer will check.
  • • Track denials by panel and by payer, not just claim by claim, so systemic coding or documentation gaps get fixed once instead of appealed repeatedly.

Why NGS billing has become its own specialty

Next-generation sequencing used to be billed the way most molecular tests were billed: with a handful of CPT codes and a lot of guesswork. That approach doesn’t work anymore, and it hasn’t for a while.

Two things changed the landscape. First, the American Medical Association restructured molecular pathology coding starting in 2013, replacing the old “stacking” codes with a tiered system, plus a growing category of test-specific PLA codes. Second, payers responded to the explosion of genomic testing volume by building entirely separate infrastructure, registries, medical policies, and prior authorization programs, just to manage molecular and genetic claims.

The result is a billing environment where the same clinical test can be coded three different ways depending on the panel’s design, and where the same panel can require prior authorization from one payer and none at all from another. Add in payer-specific gene count thresholds, Z-Code identifier requirements, and documentation rules that vary by Medicare Administrative Contractor (MAC), and you have a coding and billing complexity level that rivals anything in oncology drug administration.

Understanding that complexity, and building workflows around it instead of around hope, is what separates laboratories with clean first-pass reimbursement from laboratories chasing appeals every quarter.

The NGS reimbursement journey, from order to payment

Before getting into codes and denial reasons, it helps to see the whole picture. NGS reimbursement is not one event. It’s a chain, and a break at any link affects everything downstream. Written out as a chain, it looks like this: 

eligibility verification → benefits check → prior authorization → specimen collection and sequencing → medical necessity documentation → code selection → claim submission → payer adjudication → payment or denial → appeal, if needed. 

That front end, eligibility and benefits verification, is easy to underweight because it happens before any coding or billing work begins, but it’s where a large share of downstream denials are actually decided. Confirming coverage, plan type, and authorization requirements before the specimen is even collected is what prevents a laboratory from performing, and paying for, a test that was never going to be reimbursed as ordered.
Most billing teams treat these as separate departments: intake, coding, billing, and denial management. But NGS claims punish that separation. A prior authorization obtained for the wrong gene count, a coding decision made without knowing the payer’s Z-Code requirement, or a denial appeal filed without the original medical necessity documentation on hand, these all trace back to treating the journey as disconnected steps instead of one continuous process.

Not all NGS panels are the same test, and billing shouldn’t treat them that way

“NGS billing” gets discussed as though it’s one thing, but the coding and documentation path depends heavily on what kind of NGS test was actually ordered. It’s worth distinguishing the major categories up front, because the medical necessity criteria, the typical CPT/PLA pathway, and the prior authorization thresholds differ across them:

  • Oncology, somatic tumor profiling. Panels ordered to guide treatment selection for an existing cancer diagnosis, often tied to comprehensive genomic profiling or targeted gene panels. Medical necessity documentation typically centers on the pathology report and the treatment decision the results will inform.
  • Hereditary and germline testing. Panels ordered to assess inherited cancer risk or other inherited conditions, where medical necessity usually depends on documented family history, personal history, or genetic counseling notes rather than an existing diagnosis.
  • Pharmacogenomic testing. Panels assessing how a patient metabolizes specific medications, coded very differently from tumor or hereditary panels and increasingly represented by dedicated PLA codes.
  • Infectious disease NGS. Panels used for pathogen identification or characterization, which usually fall under a separate section of the CPT code set entirely and follow different medical necessity logic than oncology or hereditary panels.
  • Hematologic malignancy panels. Panels built around genes relevant to leukemias and related conditions, frequently updated as new prognostic and treatment-relevant markers are added to clinical guidelines.
  • Comprehensive genomic profiling and exome/genome-scale panels. Broad panels or exome-level sequencing, which tend to draw the most scrutiny on prior authorization gene-count thresholds and the highest documentation bar for medical necessity.

The coding principles in this article, PLA versus GSP versus Tier 1/Tier 2 versus 81479, apply across all of these categories, but the specific code, the specific payer policy, and the specific documentation payers expect will differ by test type. Treating “NGS billing” as a single workflow rather than a family of related workflows is itself a common source of avoidable denials.

Understanding the coding landscape: Tier 1, Tier 2, PLA, and the unlisted code

This is where most NGS billing problems start, so it’s worth spending real time here.

Tier 1 molecular pathology codes

Tier 1 codes, which run from CPT 81161 and again across 81200 through 81383, are analyte-specific. Each code corresponds to a named gene, like BRCA1, CFTR, or JAK2, and describes a defined analysis type for that gene. If your NGS panel happens to test a small number of genes that each have an assigned Tier 1 code, in theory you could report those codes individually. In practice, this almost never applies cleanly to a true multi-gene NGS panel, because Tier 1 codes were built for single-analyte or small-scale testing, not for panels running dozens or hundreds of genes through one sequencing workflow. Tier 1 and Tier 2 molecular pathology codes are structured differently, with Tier 2 codes (CPT 81400 through 81408) organized by levels of technical and interpretive complexity.

Tier 2 molecular pathology codes

Tier 2 codes (CPT 81400 through 81408) sit in a distinct range from Tier 1 and work differently. Instead of naming a specific gene, they’re organized by level of technical and interpretive complexity, from Level 1 (81400) up through Level 9 (81408). A gene without its own Tier 1 code gets billed under the Tier 2 level that matches its complexity, based on the AMA’s published complexity mapping, and current Medicare coverage guidance is explicit that Tier 2 codes exist specifically to report procedures not already listed among the Tier 1 codes.

Here’s the part that trips people up: Tier 2 codes were designed for single-gene analyses, not comprehensive panels. When a laboratory runs a 50-gene or 150-gene NGS panel and tries to report it as a stack of individual Tier 2 codes, payers frequently reject the claim, bundle the codes, or apply Medically Unlikely Edits (MUEs) that cap how many units can be billed together. Some payer policies explicitly limit how many Tier 1 or Tier 2 codes can be reported per encounter, and several require a modifier or a claim note explaining why multiple codes were billed together, such as Modifier 59 or the appropriate X-modifier for distinct procedural services.

The genomic sequencing procedure (GSP) codes

Sitting between Tier 2 and PLA is a category most billing guides underplay: the Genomic Sequencing Procedures and Other Molecular Multianalyte Assays codes, generally in the 81410 through 81471 range. These codes were purpose-built for panels, covering things like hereditary cardiovascular disease panels, hereditary hearing loss panels, and targeted oncology gene panels sequenced together. If your NGS panel fits one of these defined GSP code descriptions, it is usually the cleanest and most defensible option, because the code was written with panel testing in mind rather than adapted from single-gene logic.

PLA codes

Proprietary Laboratory Analyses codes are the newest and fastest-growing category. A PLA code is a five-character alphanumeric code ending in “U” (for example, 0111U), assigned to a specific, named laboratory test performed by a specific laboratory or manufacturer. Unlike Tier 1, Tier 2, or GSP codes, which describe a category of testing that any qualified lab can perform, a PLA code is tied to one proprietary test.

The PLA code set has grown quickly. The AMA’s CPT Editorial Panel established 23 new PLA codes (0552U through 0574U) effective July 1, 2025, and another 25 new PLA codes (0575U through 0599U) effective October 1, 2025, and CMS continues to add new proprietary laboratory analysis codes on a quarterly cycle in 2026. That pace matters operationally: a code your lab used correctly last quarter may be replaced, revised, or joined by a more specific code this quarter, and using an outdated code is a common, entirely avoidable denial trigger.

When a PLA code has been assigned to your laboratory’s specific panel and the payer you’re billing recognizes that code for claims processing, it’s generally the most specific and defensible reporting option available. It’s exactly what payers want to see, because it removes ambiguity about which test was actually performed. That said, PLA recognition and pricing can vary by payer and by MAC, so it’s worth confirming the code is actually accepted by the specific payer on the claim before assuming it’s automatically the right choice in every case.

The unlisted code: 81479

When no Tier 1, Tier 2, GSP, or PLA code accurately describes the panel, laboratories may use CPT 81479, the unlisted molecular pathology procedure code. However, because an unlisted code does not identify a specific molecular test by itself, the claim generally requires additional information describing the service performed and supporting why the code was selected. CMS guidance on molecular pathology and genetic testing provides documentation and billing requirements relevant to unlisted molecular pathology procedures.

For 81479 claims, laboratories should provide a clear description of the test or procedure performed and retain supporting medical records that establish the service billed. Depending on the payer and claim circumstances, additional documentation may be requested to determine pricing, coverage, or medical necessity. This makes 81479 less straightforward than reporting a specific PLA or GSP code that directly describes the test.

Treat 81479 as a last-resort coding option, rather than a convenient default. Before using it, billing teams should confirm that no more specific CPT or PLA code accurately represents the test and review the applicable payer or MAC requirements for claim descriptions, documentation, pricing, and supporting records.

A quick decision framework

SituationLikely code path
Your lab holds a payer-recognized PLA code for this exact testReport the PLA code as primary
The panel matches a defined GSP code description (e.g., a named hereditary panel)Report the GSP code
A small number of genes tested each have Tier 1 codesReport Tier 1 codes individually, checking MUE limits
Genes lack Tier 1 codes but map to defined complexity levelsReport the matching Tier 2 code(s), with documentation supporting each unit
Nothing above accurately describes the panelReport 81479 once, with a full procedure description and supporting documentation

PLA vs. Tier 2: the decision that determines your reimbursement rate

Since this is the coding decision laboratories struggle with most, it deserves its own close look.

The instinct for many billing teams is to default to Tier 2 codes because they feel more “standard.” That instinct is understandable but often costly. Here’s why the PLA-versus-Tier-2 decision matters so much:


Specificity drives approval:
A PLA code tells the payer exactly which test was run, by which lab, using which methodology. A stack of Tier 2 codes tells the payer “we did some complexity-level testing,” which forces the payer’s system, or a human reviewer, to guess at what was actually performed. Ambiguity is the number one driver of manual review and delay.

Bundling risk is higher with Tier 2 stacking: When a laboratory reports multiple Tier 2 codes for a single NGS panel run, payer claims-editing software frequently applies Procedure-to-Procedure (PTP) edits or Medically Unlikely Edits that reduce or deny some of the units. This isn’t necessarily wrong on the payer’s part. It’s often the intended function of those edits: preventing what looks like unbundled billing for what was, technically, one sequencing run.

PLA codes reduce audit exposure: Because a PLA code maps to one specific, registered test, it’s much easier for both the lab and the payer to document medical necessity, track utilization, and defend the claim if it’s later reviewed. Tier 2 stacking, by contrast, invites the question “why were nine separate procedures billed for what appears to be one panel?”

Not every panel qualifies for a PLA code: Getting a PLA code requires an application to the AMA and, for Medicare purposes, typically requires registration through the MolDX program (discussed below) to receive pricing and coverage. Smaller or newer laboratories sometimes haven’t gone through this process yet, which is a legitimate reason to fall back to GSP, Tier 2, or 81479, but it’s worth treating PLA code acquisition as a strategic priority rather than an afterthought if your lab runs a proprietary panel repeatedly.

The safest rule of thumb: if a PLA code exists for your exact test, use it. If a GSP code accurately describes your panel, use that next. Reserve Tier 2 stacking for situations where individual genes genuinely warrant separate reporting, and always check your MAC’s or payer’s MUE table before submitting more than a couple of Tier 2 units on one claim.

MolDX and NGS billing: Z-Codes, registration, and claim requirements

If you bill Medicare or a growing list of commercial payers for molecular and genomic testing, you cannot avoid MolDX for long.

The Molecular Diagnostic Services Program (MolDX) is administered through Palmetto GBA, which also serves as a Medicare Administrative Contractor. MolDX assigns a unique five-character alphanumeric Z-Code identifier to specific molecular and genetic tests through its DEX Diagnostics Exchange registry. The Z-Code sits alongside the CPT code on a claim and tells the payer, with precision, exactly which test was performed, similar in spirit to what a PLA code does, but functioning as an additional identifier layered on top of the CPT/HCPCS code rather than replacing it.

Laboratories that skip this step often see claims pend, get priced incorrectly, or get denied outright, not because the test wasn’t covered, but because the payer’s system couldn’t identify what was billed. MolDX Z-Code registration can therefore become a critical part of the molecular billing workflow.

Two things make this more than a niche administrative detail:

First, Medicare MACs that follow MolDX require registration and, in many cases, a Z-Code for coverage and correct payment of molecular pathology, GSP, MAAA, and PLA claims. Laboratories that skip this step often see claims pend, get priced incorrectly, or get denied outright, not because the test wasn’t covered, but because the payer’s system couldn’t identify what was billed.

Second, commercial payers have adopted the same infrastructure. UnitedHealthcare announced in 2023 that molecular and genetic test claims tied to roughly 250 CPT codes would require a Z-Code issued through the DEX registry, effective August 1 that year, and that requirement has remained a fixture of UHC’s genetic and molecular testing policy since. Other major payers, including several Blue Cross Blue Shield plans and Medicaid managed care organizations, have layered in similar Z-Code or registry-based requirements, sometimes routed through vendor platforms like Concert Genetics rather than DEX directly.

Practical takeaway: before your laboratory bills its first claim for a new NGS panel, register the test through the applicable registry (DEX/MolDX for Medicare-adjacent payers, Concert Genetics or the payer’s own portal for others that require it) and confirm which Z-Code or Genetic Testing Unit (GTU) identifier applies. Bake that identifier into your claim template so it’s included automatically, not added manually after the first round of denials teaches you the hard way.

Medicare’s coverage foundation for NGS testing

Medicare coverage for NGS as a diagnostic test rests on a specific national framework, and knowing it helps you build documentation that matches what reviewers are actually checking against.

Under the applicable National Coverage Determination, NGS as a diagnostic laboratory test is considered reasonable and necessary, and is covered nationally, when it is performed in a CLIA-certified laboratory, ordered by a treating physician, and when the NCD’s specific requirements are met, including criteria tied to cancer diagnosis and, separately, germline (inherited) testing pathways. Recovery Audit Contractor issue documentation built around this NCD specifically calls out that reviewers will check documentation against these exact requirements, including CLIA certification, treating physician order, and adherence to the applicable indications, when auditing NGS claims tied to certain PLA codes.

For Advanced Diagnostic Laboratory Tests (ADLTs), a category many high-complexity NGS panels fall into, CMS applies its own pricing and data reporting rules under the Clinical Laboratory Fee Schedule, and the reporting periods and payment determinations are updated on a recurring cycle. As of the CY 2026 CLFS update, CMS continues to run periodic data reporting windows for clinical diagnostic laboratory tests, with the most recent reporting period tied to a January through June 2025 collection window feeding into a May through July 2026 reporting cycle. If your laboratory bills ADLT-classified NGS panels, staying current on these reporting obligations is not optional. Missing a reporting period can affect pricing and, in some circumstances, coverage continuity for your test.

NGS prior authorization: requirements, thresholds, and common problems

Who requires it, and how requirements differ by payer type

Prior authorization requirements for NGS panels don’t come from a single source. They vary across the major payer categories a laboratory typically bills, and it helps to think of that landscape as a segmented framework: Medicare → Medicare Advantage → Medicaid → commercial payers → employer or third-party administrator (TPA) plans. Traditional Medicare’s requirements flow primarily from National Coverage and Local Coverage Determinations rather than a prior authorization request process in the conventional sense. 

Medicare Advantage plans, Medicaid managed care organizations, and commercial payers each set their own medical policies on top of that baseline, which means the same panel, billed for the same clinical indication, can face a prior authorization requirement under one plan type and none at all under another. Confirming which category a given patient’s coverage falls into, before ordering the panel, is a foundational step that’s easy to skip when a lab is moving quickly.

This is the second major complexity driver named in the coding and billing complexity angle for this article, and for good reason. Prior authorization for NGS panels is not a simple yes-or-no gate. It’s a set of thresholds, and understanding where those thresholds sit for your major payers is often the difference between a same-week approval and a six-week delay.

What typically triggers prior authorization

Most payer medical policies for molecular oncology or genetic testing key their prior authorization requirements to a combination of factors rather than a single rule:

  • Gene count. Several major commercial payers, including UnitedHealthcare’s molecular oncology testing policy, distinguish between smaller panels and larger ones, applying different documentation or medical necessity thresholds depending on how many genes the multigene NGS panel includes. A common threshold seen across payer policy language separates panels of 50 genes or fewer from larger panels, with larger panels facing a higher bar for medical necessity documentation, particularly regarding prior molecular profiling already performed on the same tumor.
  • Prior testing on the same specimen or tumor. Policies frequently require confirmation that no prior molecular profiling has already been performed on the same tumor before authorizing a broad panel, to prevent duplicate testing.
  • Germline versus somatic intent. Hereditary panels ordered for germline risk assessment are often evaluated against different criteria (family history, personal history, specific syndrome criteria) than somatic tumor profiling panels ordered for treatment selection.
  • Site of service. Testing ordered as part of an inpatient stay, outpatient visit, or through a specific specialist (oncologist, genetic counselor, maternal-fetal medicine physician) can trigger different authorization pathways.
  • CPT code itself. Some payers tie prior authorization directly to specific codes. For example, state Medicaid programs have opened or restricted specific Tier 1 codes, like 81206 and 81207 for BCR/ABL1 testing, to prior authorization requirements as recently as late 2024, showing that even single-gene codes tied into NGS-adjacent workflows aren’t exempt from this scrutiny.

The documentation payers actually want

Across payers, the documentation requested for NGS prior authorization tends to cluster around the same core set of items:

  • A molecular diagnostic clinical history form or equivalent clinical summary
  • The most recent pathology report, when oncology testing is involved
  • Relevant clinic encounter notes establishing the clinical indication
  • Genetic counseling or medical genetics consultation notes, when applicable
  • Confirmation of no duplicate prior testing on the same specimen, where policy requires it
  • The specific panel name, gene list, and, where available, the Z-Code or PLA code identifying the exact test

Submitting a prior authorization request without one of these pieces, especially the pathology report for oncology panels or genetic counseling documentation for hereditary panels, is one of the single most common reasons authorization requests bounce back for additional information, adding days or weeks to the process.

Prior authorization thresholds are moving, and not always upward

It’s worth knowing that the direction of travel for prior authorization isn’t uniformly getting stricter. UnitedHealthcare announced in 2023 that it would eliminate prior authorization requirements for hundreds of genetic testing codes, codes that had generated tens of thousands of prior authorization requests annually from commercial and Medicaid members, as part of a broader effort to reduce administrative burden. Other payers have made similar targeted rollbacks for specific code sets, while simultaneously tightening requirements elsewhere, such as adding Z-Code mandates.

The practical implication is that a prior authorization matrix your laboratory built even a year or two ago may already be out of date. Payer policy changes, sometimes announced with only a few weeks’ notice, as was the case with UnitedHealthcare’s original Z-Code mandate in 2023. A laboratory that treats its prior authorization requirements list as a living document, checked quarterly against each major payer’s current molecular and genetic testing policy, avoids a lot of otherwise preventable denials.

Common NGS billing errors

Before getting into denial traps specifically, it’s worth naming the coding and process errors that tend to cause them in the first place.

Using an outdated or retired code: With new PLA codes arriving quarterly and CPT making periodic revisions to Tier 1 and Tier 2 descriptors, a code that was correct six months ago can become incorrect without any change in your lab’s actual testing process.

Reporting Tier 2 codes as if they were Tier 1: Billing a Tier 2 complexity-level code without ensuring the gene actually lacks a Tier 1 equivalent invites both denials and, in an audit context, questions about upcoding.
Missing the procedure description on 81479 claims. This is one of the most avoidable errors in the entire NGS billing landscape, and one of the most common.

Failing to include the Z-Code or GTU identifier where a payer requires it: Especially for UnitedHealthcare and MolDX-aligned MACs, this single missing data point causes a disproportionate share of pends and denials.

Billing multiple units without checking MUE limits: Medically Unlikely Edits exist specifically to catch this, and claims that exceed them are typically denied outright rather than partially paid.

Inconsistent diagnosis coding: ICD-10 codes attached to the claim need to logically support the specific test ordered. A germline hereditary cancer panel billed against a diagnosis code that only supports acute treatment, rather than risk assessment or family history, is a mismatch payers catch quickly.

Not verifying benefits before the specimen is even collected: By the time coding and prior authorization become relevant, it’s often too late to change course on a specimen collection decision, so front-end verification has to happen before, not after.

Why are NGS claims denied? The core denial traps

This is the question patients, laboratory billing staff, and administrators all eventually ask, usually after seeing an unexpectedly large denial batch. The reasons cluster tightly.

Missing or expired prior authorization

One of the most common denial scenarios for NGS panels is straightforward: the test required prior authorization, and either it wasn’t obtained, it expired before the specimen was processed, or it was obtained for a different panel than what was ultimately run. Authorizations are often tied to a specific CPT or PLA code and a specific gene list. If the lab’s final panel design changes even slightly from what was authorized, a denial or a request for additional review is a common result.

Incorrect CPT, PLA, or Tier 2 code selection

As covered above, code selection errors, using an unlisted code when a specific one exists, stacking Tier 2 codes without justification, or reporting an expired PLA code, are a leading cause of denial, and they’re almost entirely preventable with a current, well-maintained coding reference specific to each panel your lab offers.

Insufficient medical necessity documentation

Even a correctly coded, properly authorized test can be denied if the claim, or the chart behind it, doesn’t clearly establish why the test was necessary for this specific patient. This is especially common with hereditary panels, where payers want to see documented family history or personal history criteria that match published guidelines (such as NCCN criteria for hereditary cancer panels), not just a general order for “genetic testing.”

Payer-specific coverage restrictions

Not every payer covers every panel, even when Medicare or another major payer does. Regional coverage differences, local coverage determinations issued by specific MACs, and commercial payer medical policy exclusions all create situations where an identical test, ordered for an identical clinical indication, is covered by one payer and denied by another. Verifying payer-specific policy before the test is run, not after the claim is denied, is the most reliable way to avoid this category of denial.

Incorrect diagnosis linkage

Denials frequently cite a mismatch between the ICD-10 diagnosis code submitted and the CPT/PLA code billed. This often isn’t a documentation failure so much as a coding failure. Someone chose the wrong diagnosis code, or an outdated one, to pair with a correctly performed test.

Missing Z-Code where applicable

Worth repeating on its own because it has become a significant NGS-specific denial trigger. When a payer’s molecular and genetic testing policy requires a Z-Code identifier, and it is missing from the claim, the result may be a denial or a request for additional information, even when medical necessity is otherwise well documented. These molecular testing billing errors can also create problems when a laboratory is selected for a Medicare Targeted Probe and Educate review. These recurring issues highlight why specialized molecular lab billing services are important for accurate claim submission and effective denial prevention.

Incorrect units or duplicate billing

Billing more units of a code than the MUE table allows, or billing what looks like the same test twice (once as part of the panel and once as an individual gene stack) triggers claims-editing software before a human ever reviews the file.

Incomplete supporting documentation on submission

Payers increasingly expect supporting documentation, pathology reports, consultation notes, and clinical history forms, to accompany the claim itself, not to be produced only after a denial and an appeal request. Waiting for the payer to ask is a slower, costlier path than submitting complete documentation up front.

A worked example: coding the same panel two different ways

It helps to see the PLA-versus-Tier-2 decision play out on an actual panel, because the abstract version of this advice is easy to nod along to and still get wrong in practice.

Picture a 75-gene solid tumor NGS panel run by a reference laboratory for a patient with newly diagnosed non-small cell lung cancer. The ordering oncologist needs actionable variant information to guide targeted therapy selection.


The Tier 2 stacking approach:
A less experienced coder might look at the gene list, note that several genes lack their own Tier 1 code, and report a handful of Tier 2 codes at varying complexity levels to represent the panel, sometimes adding units to reflect the number of genes analyzed. This approach almost always runs into trouble. The payer’s claims-editing software sees multiple molecular pathology codes reported together on the same date of service for what is clearly one sequencing workflow, and either bundles them, applies an MUE reduction, or flags the claim for manual review asking why so many procedures were billed for one specimen. Even when it gets paid, it usually gets paid slowly and at a level that undervalues the actual complexity of a 75-gene panel.

The PLA-first approach: If the reference laboratory has registered this specific panel and received a PLA code, that single code is reported instead. It’s already been reviewed and priced (or is in the process of being priced) with this exact test in mind. The claim includes the panel’s Z-Code identifier in the appropriate field, the diagnosis code reflects the lung cancer diagnosis and the intent to guide treatment (not just a generic “genetic testing” indication), and supporting documentation, the pathology report confirming the diagnosis and the oncologist’s note establishing that targeted therapy selection depends on the results, is attached at submission. This claim has a dramatically higher likelihood of clean, timely adjudication, because every element of it answers a question the payer would otherwise have to ask manually.

If no PLA code exists yet: The next best option is checking whether the panel matches a defined GSP code description. If it genuinely doesn’t, and the lab is still working toward PLA registration, then 81479 becomes the fallback, but with the discipline described earlier: one unit, a complete procedure description identifying the panel by name and gene count, and the same supporting documentation bundle attached up front rather than produced later during an appeal.

The lesson from this example generalizes well beyond lung cancer panels. The coding decision isn’t really about which code is “allowed.” It’s about which code gives the payer the least reason to ask a follow-up question before paying the claim.

A documentation checklist worth keeping at every workstation

Billing teams that consistently avoid the denial traps above tend to work from some version of the same checklist before a claim goes out the door. It’s worth adapting this to your lab’s specific panels and posting it somewhere your coders actually see it.
CheckWhy it matters
Is this the current, non-retired code for this exact panel?Quarterly PLA updates retire and replace codes regularly
If using 81479, is there a complete procedure description attached?A missing description is a frequent cause of pends or denials on unlisted-code claims
Does this claim need a Z-Code or GTU identifier, and is it included?A large share of MolDX-aligned and UHC denials trace to this one field
Was prior authorization obtained for this specific panel and gene list?Authorizations tied to a different gene count or panel name won’t cover the claim as billed
Does the diagnosis code logically support the test ordered?Mismatched diagnosis and procedure codes are a frequent, avoidable denial reason
Is supporting documentation (pathology report, clinical notes, counseling notes) attached now rather than held for a possible appeal?Front-loading documentation shortens the payment cycle significantly
Does the gene count trigger a payer-specific threshold (commonly around 50 genes) requiring extra justification?Large panels often face a higher medical necessity bar than smaller ones
Have Medically Unlikely Edit limits been checked for any multi-unit or multi-code claim?Exceeding a payer’s MUE limits typically results in denial or reduction of the excess units
None of these checks take more than a minute or two individually. The value comes from running all of them, on every claim, every time, rather than treating them as things to remember only after a denial teaches the lesson the hard way.

Denial management: what to do after the denial hits

Even a well-run NGS billing operation will see denials. The difference between a lab that recovers that revenue and one that writes it off usually comes down to process, not effort.

Categorize before you appeal: Not every denial deserves the same response. A missing Z-Code denial can often be corrected and resubmitted quickly. A medical necessity denial requires a substantive appeal with supporting documentation and, sometimes, a peer-to-peer review. Sorting denials into categories before assigning appeal work prevents wasted time on claims that need a simple correction, not a full appeal letter.

Build appeal documentation as a standing packet, not a scramble: For panels your lab runs frequently, keep a template appeal packet ready that includes the panel’s clinical rationale, relevant published guideline citations (NCCN, ACMG, or specialty-specific criteria), and the standard documentation the payer typically requests. This turns a multi-day appeal preparation task into something closer to an hour.

Track denial reasons at the panel level, not just the claim level: If a specific 150-gene panel is getting denied repeatedly for exceeding a payer’s 50-gene threshold without adequate prior documentation, that’s a pattern worth fixing at the ordering and pre-authorization stage, not something to keep appealing one claim at a time.

Know your appeal deadlines cold: Medicare and commercial payer appeal windows vary, and missing a deadline converts a winnable appeal into a permanent write-off. Build deadline tracking into your claims management system rather than relying on staff memory.

Escalate systemic issues, not just individual claims: If a payer’s claims-editing system is consistently misapplying an MUE limit to a legitimately reported multi-gene panel, that’s worth raising with the payer’s provider relations team directly, not just fighting claim by claim indefinitely.

These issues are rarely isolated coding problems: They can originate anywhere from eligibility verification and prior authorization through claim submission, payer adjudication, and denial follow-up. For laboratories running significant NGS volumes, that reality is exactly why specialized molecular-testing revenue cycle management has become less of a luxury and more of an operational necessity.

When to outsource NGS billing

Not every laboratory needs a dedicated outside billing partner, but there are clear signals that it’s worth exploring:

  • Your denial rate on NGS-specific claims is meaningfully higher than your overall lab denial rate.
  • Staff are spending disproportionate time chasing prior authorizations or appeals for a small number of high-value panels.
  • Your lab has recently launched a new proprietary panel and hasn’t yet secured PLA code recognition or Z-Code registration.
  • You’re expanding into new payer contracts or new states and don’t have visibility into each payer’s current gene count thresholds and documentation requirements.
  • Quarterly PLA code updates keep catching your team by surprise rather than being tracked proactively.

A specialized NGS billing and revenue cycle management partner brings something a general laboratory billing team often can’t maintain internally: continuous tracking of quarterly PLA code changes, established relationships and workflows for MolDX and DEX registration, payer-specific prior authorization matrices that get updated as policies shift, and denial management processes built specifically around molecular and genomic testing rather than general laboratory claims.

How to choose an NGS billing partner

If you’re evaluating outside support for NGS billing and RCM, a few questions separate genuinely specialized partners from general laboratory billers who’ve simply added “genomics” to their service list:

Do they actively track and apply quarterly PLA code releases, or do they rely on you to flag code changes?
Can they demonstrate a working process for MolDX registration and Z-Code or GTU identifier management?

  • Do they maintain payer-specific prior authorization thresholds (gene count limits, documentation requirements) for your top payers, updated on a defined cadence?
  • What’s their track record on first-pass clean claim rates specifically for molecular and genomic testing, not laboratory billing generally?
  • How do they structure denial management? Is it reactive claim-by-claim work, or do they identify and correct systemic coding and documentation patterns?

Laboratories running significant NGS panel volume, whether that’s a hospital-based molecular pathology lab, an independent reference laboratory, or a company commercializing a proprietary panel, tend to see the clearest return from specialized NGS billing and RCM support precisely because the coding decisions (PLA versus Tier 2), the prior authorization thresholds, and the denial patterns are so specific to this test category. General laboratory billing expertise, while valuable, often doesn’t carry the depth needed to catch a missing Z-Code or correctly navigate a payer’s 50-gene threshold before the claim goes out the door.

If any of the denial patterns or coding questions above sound familiar, it’s worth getting a second set of eyes on your current process. Request an NGS Billing and Denial Risk Assessment to see exactly where your panels are losing reimbursement, whether that’s a coding gap, a missing Z-Code registration, or a prior authorization threshold your team hasn’t caught yet. It’s a practical starting point before deciding whether to build this expertise in-house or bring in a specialized partner.

Bringing it all together

NGS panel billing rewards precision at every step. Choosing the most specific applicable code, registering applicable tests through MolDX or the relevant payer registry, and attaching complete medical necessity documentation before submission can help laboratories build a more defensible claims process. CMS’s NGS medical necessity and documentation requirements provide a Medicare reference point for evaluating whether NGS testing meets applicable coverage requirements. What makes NGS billing genuinely hard is doing all of it consistently, across every panel, every payer, and every quarterly code update, without letting any single link in that chain slip.

Laboratories that build that discipline into their process see it show up directly in their numbers: fewer denials tied to preventable coding or documentation gaps, faster payment cycles, and a much smaller appeals backlog. For laboratories running significant NGS volume without that infrastructure in place yet, partnering with a team that specializes in molecular and genomic testing revenue cycle management is often the fastest, most reliable way to close that gap and protect the reimbursement these tests have already earned.

Frequently Asked Questions

What CPT codes are used for NGS panels?

There isn’t one universal answer, and that’s the point. Depending on the specific panel, NGS testing may be billed under a PLA code specific to that proprietary test, a Genomic Sequencing Procedure code that matches a defined panel category, a combination of Tier 1 codes for genes with existing analyte-specific codes, Tier 2 codes based on complexity level for genes without their own code, or, when nothing else fits, the unlisted molecular pathology code 81479.
Often, yes, though it depends heavily on the payer, the panel size, and the clinical indication. Medicare generally does not require prior authorization for covered diagnostic laboratory tests in the traditional sense, but coverage is contingent on meeting National Coverage Determination criteria. Commercial payers vary widely; some require prior authorization for any multigene panel above a certain size (commonly around 50 genes), while others have specifically removed prior authorization requirements from large blocks of genetic testing codes in recent years.
The most frequent reasons are missing or mismatched prior authorization, incorrect code selection (particularly PLA versus Tier 2 confusion, or defaulting to 81479 without proper documentation), insufficient medical necessity documentation, payer-specific coverage exclusions, incorrect diagnosis code linkage, and missing Z-Code identifiers where a payer requires one.
Typically a combination of the ordering clinician’s clinical notes establishing the indication, a pathology report for oncology-related testing, family and personal history documentation for hereditary panels, genetic counseling notes where applicable, and evidence that the panel size and content match the clinical question being asked. CMS’s NGS medical necessity and documentation requirements provide an important Medicare reference point for these claims.
Whenever your laboratory has been assigned a PLA code for the specific proprietary test being performed. PLA codes are the most specific option available and generally reduce ambiguity, denial risk, and audit exposure compared to reporting a stack of Tier 1 or Tier 2 codes for the same panel.
A molecular pathology code (Tier 1, Tier 2, or GSP) describes a category or level of testing that any qualified laboratory can perform and bill. A PLA code is assigned to one specific, named test offered by one specific laboratory or manufacturer. Molecular pathology codes are broader and more interchangeable across labs; PLA codes are narrow, specific, and tied to a single test’s registration.
Medicare reimbursement for NGS is governed primarily by the applicable National Coverage Determination and, for many high-complexity tests, the Advanced Diagnostic Laboratory Test pathway under the Clinical Laboratory Fee Schedule, with MolDX and Z-Code registration playing a major role in correct pricing for MolDX-aligned MACs. Commercial payers set their own medical policies, which can include different gene count thresholds, different prior authorization triggers, and their own registry or identifier requirements, such as UnitedHealthcare’s Z-Code mandate tied to roughly 250 CPT codes.
Using an outdated PLA code after a quarterly update, reporting Tier 2 codes as a substitute for a more specific PLA or GSP code, omitting the required procedure description on unlisted code 81479 claims, leaving out a required Z-Code identifier, exceeding Medically Unlikely Edit limits, and mismatching diagnosis codes to the test performed.
By verifying benefits and prior authorization requirements before specimen collection whenever possible, maintaining an up-to-date, panel-specific coding reference that reflects the current quarter’s PLA code updates, registering tests through DEX/MolDX or the applicable payer registry to secure Z-Code identifiers, attaching complete medical necessity documentation at the time of submission rather than waiting for a denial, and reviewing denial patterns regularly to catch systemic coding or documentation gaps before they compound across hundreds of claims.

Your Trusted Lab Billing Partner

Book Your Free Consultation

Book Consultation Today!

Book Consultation Today!